Vor BiopharmaVOR
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Employees: 168
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
926% more call options, than puts
Call options by funds: $5.27M | Put options by funds: $514K
113% more capital invested
Capital invested by funds: $43.1M [Q1] → $91.8M (+$48.7M) [Q2]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
2.49% less ownership
Funds ownership: 48.13% [Q1] → 45.64% (-2.49%) [Q2]
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
24% less funds holding
Funds holding: 45 [Q1] → 34 (-11) [Q2]
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth | 41%upside $3 | Buy Reiterated | 14 Aug 2025 |
Baird Jack Allen | 53%downside $1 | Neutral Maintained | 27 Jun 2025 |
Wedbush David Nierengarten | 81%downside $0.40 | Neutral Reiterated | 26 Jun 2025 |
Financial journalist opinion
Based on 5 articles about VOR published over the past 30 days









